Last reviewed · How we verify
Methyldihydromorphinone (METOPON)
Methyldihydromorphinone (generic name: METOPON) is a drug. It is currently in Phase 2 development.
METOPON is a synthetic opioid that binds to opioid receptors in the brain to produce analgesic effects.
Methyldihydromorphinone, also known as Metopon, is a small molecule. It is a synthetic opioid with various synonyms, including 5-METHYLDIHYDROMORPHINONE, IDS-NM-006, and METHYLDIHYDROMORPHINONE.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | METOPON |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 2 |
Mechanism of action
Imagine your brain has special locks called opioid receptors. METOPON is a key that fits into these locks, which helps to block pain signals. This can provide relief from pain, but it can also have side effects and risks, especially when used improperly.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methyldihydromorphinone CI brief — competitive landscape report
- Methyldihydromorphinone updates RSS · CI watch RSS
Frequently asked questions about Methyldihydromorphinone
What is Methyldihydromorphinone?
How does Methyldihydromorphinone work?
What is the generic name of Methyldihydromorphinone?
What development phase is Methyldihydromorphinone in?
Related
- Therapeutic area: All drugs in Pain
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing